Copyright
©The Author(s) 2016.
World J Transplant. Dec 24, 2016; 6(4): 703-711
Published online Dec 24, 2016. doi: 10.5500/wjt.v6.i4.703
Published online Dec 24, 2016. doi: 10.5500/wjt.v6.i4.703
Table 1 Relationship between various parameters at the time of liver transplantation and the incidence of hepatic steatosis on 10-year post-liver transplantation biopsy
All subjects n = 72 | No HS n = 48 | HS n = 24 | P1 | |
Age (yr) | 35 ± 19 | 32 ± 21 | 42 ± 12 | 0.04 |
Gender (female) | 52% | 60% | 71% | NS |
Disease | ||||
Acute hepatic failure | 24% | 27% | 17% | NS |
Primary biliary cirrhosis | 25% | 25% | 25% | NS |
HBV-related cirrhosis | 8% | 6% | 12% | NS |
Autoimmune cirrhosis | 7% | 6% | 8% | NS |
Biliary atresia | 5% | 8% | 0% | NS |
HCV-related cirrhosis | 12% | 6% | 25% | NS |
Metabolic disease (Wilson disease) | 1% | 2% | 0% | NS |
Alcohol related cirrhosis | 1% | 2% | 0% | NS |
Primary sclerosing cholangitis | 4% | 4% | 4% | NS |
Cryptogenic cirrhosis | 2% | 4% | 0% | NS |
Hepatocellular carcinoma | 8% | 8% | 8% | NS |
ABO compatible | 97% | 96% | 100% | NS |
Donor age (years) | 27 ± 11 | 27 ± 12 | 27 ± 10 | NS |
Donor gender (female) | 41% | 42% | 39% | NS |
Urgency | 25% | 27% | 21% | NS |
Cold ischemic time (min) | 410 ± 212 | 406 ± 215 | 429 ± 214 | NS |
Reperfusion biopsy2 | ||||
Steatosis (≥ 10%) | 18% | 15% | 22% | NS |
% of steatosis | 24 ± 15 | 31 ± 16 | 16 ± 8 | NS |
Reperfusion lesions | ||||
Mild | 26% | 31% | 17% | NS |
Moderate to severe | 60% | 50% | 79% | NS |
Table 2 Relationship between various parameters at 10-year post-liver transplantation and the incidence of hepatic steatosis on 10-year post-liver transplantation biopsy
All subjects n = 72 | No HS n = 48 | HS n = 24 | P1 | |
Age at the time of survey | 49 ± 15 | 47 ± 15 | 53 ± 12 | NS |
≥ 60 yr aged patients | 28% | 27% | 29% | NS |
Histological lesions | ||||
Steatosis | 33% | - | 100% | |
Macrovacuolar | 28% | - | 82% | |
Microvacuolar | 1% | - | 4% | |
Combined Mac-Mic | 4% | - | 14% | |
Initial and 10-yr maintained steatosis | 8% (5 pat.) | 0% | 22% | 0.002 |
Fibrosis (F1-F4) | 53% | 44% | 71% | 0.03 |
F1-F2 | 40% | 35% | 50% | NS |
F3-F4 | 13% | 8% | 21% | NS |
Combined fibrosis-steatosis | 24% | 0% | 71% | < 0.0001 |
HCV(+) Fibrosis | 44% | 31% | 71% | < 0.001 |
Bile duct lesions | 36% | 42% | 25% | NS |
Minimal change | 23% | 27% | 17% | NS |
Other potential steatosis factors | ||||
BMI (kg/m2) | 22.4 ± 3.8 | 22.3 ± 3.9 | 22.6 ± 3.4 | NS |
Underweight (BMI ≤ 18.5) | 13% | 17% | 4% | |
Normal weight (BMI = 18.5-24.9) | 69% | 65% | 79% | NS |
Overweight (BMI = 25-29.9) | 14% | 14% | 13% | |
Obesity (BMI ≥ 30) | 4% | 4% | 4% | |
HCV infection (de novo or recurrence) | 57% | 46% | 79% | 0.007 |
Arterial hypertension | 53% | 52% | 54% | NS |
Glycemia (mmol/L) | 5.4 ± 2.0 | 5.1 ± 0.9 | 6.2 ± 3.2 | NS |
Diabeties mellitus | 10% | 8% | 13% | NS |
Maintenance immunosuppresssion | ||||
Cyclosporine A | 96% | 96% | 96% | NS |
Dosage (mg) | 129.8 ± 58.1 | 135.0 ± 61.5 | 119.5 ± 50.4 | NS |
Prednisolone | 93% | 96% | 88% | NS |
Dosage (mg) | 6.8 ± 3.1 | 6.9 ± 3.2 | 6.7 ± 2.9 | NS |
Azathioprine | 43% | 40% | 50% | NS |
Dosage (mg) | 48.4 ± 15.7 | 51.3 ± 15.5 | 43.8 ± 15.5 | NS |
Table 3 Social life factors and hepatic steatosis at 10-year biopsy
All subjects n = 72 | No HS n = 48 | HS n = 24 | P1 | |
Work | ||||
Employed | 33% | 39% | 23% | NS |
Homemaker | 13% | 17% | 4% | NS |
Student full/part-time | 3% | 4% | 0% | NS |
Unemployed | 20% | 19% | 23% | NS |
Retired | 30% | 21% | 50% | 0.03 |
No. of years worked | 17.9 ± 12.7 | 16.4 ± 12.6 | 20.9 ± 12.5 | NS |
Alcohol and smoking | ||||
Alcohol consumption | 21% | 17% | 30% | NS |
No. of drinks2/d in drinkers | 1.1 ± 0.3 | 1.0 ± 0.0 | 1.2 ± 0.4 | NS |
Tobacco smokers | 17% | 15% | 21% | NS |
Cigarettes/d in smokers | 1.9 ± 0.7 | 2.1 ± 0.7 | 1.6 ± 0.9 | NS |
Table 4 Univariate analysis of subjective variables associated with hepatic steatosis at 10-year biopsy
QOL criteria | Univariate P |
Physical distress | |
Muscle weakness | 0.04 |
Abdominal pains or discomfort | < 0.0001 |
Abdominal swelling or bloating | 0.04 |
Joint aches or pains | < 0.001 |
Headaches | 0.03 |
Poor or blurred vision | 0.03 |
Change in facial appearance | < 0.001 |
Fluid retention or swelling of ankles | 0.02 |
Psychological distress | |
Sleeplessness or insomnia | 0.03 |
Nervousness, anxiety | 0.009 |
Feeling depressed, sad or blue | < 0.01 |
Low satisfaction with life as a whole | 0.02 |
Personal function | |
Health currently limits the kind of vigorous activities such as running, heavy lifting or sport | < 0.001 |
Social and role function | |
Decreased interest in sex | 0.003 |
Problem with sex life | 0.04 |
General health perception | |
Bodily pain during the last month | < 0.01 |
Table 5 Multivariate analysis of independent factors of hepatic steatosis at 10-year biopsy
Factors | Multivariate P |
Objective factors | |
Retirement | 0.04 |
Hepatitis C virus infection (de novo or recurrence) | < 0.01 |
Subjective factors | |
Abdominal pains or discomfort | < 0.01 |
Joint aches or pains | 0.04 |
- Citation: Karam V, Sebagh M, Rifai K, Yilmaz F, Bhangui P, Danet C, Saliba F, Samuel D, Castaing D, Adam R, Feray C. Quality of life 10 years after liver transplantation: The impact of graft histology. World J Transplant 2016; 6(4): 703-711
- URL: https://www.wjgnet.com/2220-3230/full/v6/i4/703.htm
- DOI: https://dx.doi.org/10.5500/wjt.v6.i4.703